Supercharged immune cells target stubborn cancers in new trial
NCT ID NCT05989204
Summary
This early-stage trial is testing the safety and finding the right dose of a new type of CAR-T cell therapy for adults with certain aggressive B-cell lymphomas that have come back or not responded to other treatments, including prior CAR-T therapy. The therapy involves modifying a patient's own immune cells to better target and fight cancer cells. The main goals are to see if the treatment is safe and to learn how the body handles it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.